The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is a novel instrument to evaluate endoscopic disease activity. It has been demonstrated to outperform the more widely used Mayo endoscopic score (MES) in predicting long-term prognosis, including the need for colectomy. Despite its potential benefits, many clinicians still prefer to use MES because its operating characteristics are better defined and its grades are more readily applicable to clinical decision-making. The aims of our study were to quantify the UCEIS cutoff most closely associated with the need for treatment escalation and to perform a validation exercise using MES and clinical, biochemical, and histological measures of disease activity.
INTRODUCTION
The importance of endoscopic evaluation as part of the clinical management of ulcerative colitis (UC) is becoming increasingly appreciated. 1 Many clinicians now consider proactive and repeated evaluation to be an essential part of tight disease control, and, as such, this type of approach has been de Jong et al advocated in international expert consensus recommendations. 2 Endoscopic healing has been demonstrated to be associated with favorable short-and long-term outcomes, including symptom resolution, 3 colectomy rates, 4 and development of colorectal cancer, 5 and is now an additional therapeutic goal, together with clinical remission. 2 Although there are several indices for the measurement of endoscopic activity in UC, 6 by far the most widely used is the endoscopic component of the Mayo Clinic Index. 7 Introduced in 1978, the Mayo Clinic Index consists of 4 descriptors: stool frequency, rectal bleeding, physician's global medical assessment, and endoscopic evaluation of the rectosigmoid mucosa. Each component has an individual number of stratifications, which leads to a total score ranging from 0 to 12. The Mayo endoscopic score (MES) consists of a 4-point scale, defining 4 grades of endoscopic disease activity: inactive (grade 0), mild (grade 1), moderate (grade 2), and severe disease (grade 3). These grades are based on endoscopic findings such as bleeding, ulceration, erosions, loss of vascular pattern, erythema, and friability. Despite being routinely used in clinical practice and to assess eligibility and outcomes in clinical trials, this index has not undergone a complete validation process. In addition, wide interobserver variation has been demonstrated. 8 In view of these shortcomings, Travis et al. devised and internally validated a novel instrument to evaluate endoscopic disease activity, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). 8, 9 This score includes 3 descriptors that were demonstrated to have optimal agreement in predicting disease severity, namely vascular pattern, bleeding, and erosions or ulcerations. Each descriptor is scored individually in the worst affected region and stratified into ascending grades of severity (Fig. 1) . The combined total of these results in the final UCEIS score ranges from 0 to 8, with higher scores denoting increasing disease activity.
In recent studies, the UCEIS has been demonstrated to outperform the MES for predicting long-term prognosis, 10, 11 including the need for colectomy. 12 Not only was the UCEIS internally validated as part of its development, but it is also likely to be more responsive than the MES by virtue of its greater number of stratifications (0-8, as opposed to 0-3). In addition, its precise definitions for each item afford it a level of detail, subtlety, and granularity that is missing from the MES. For example, if ulceration is present, an MES of 3 is appropriate. However, if the colonoscopy is repeated and the same ulcer is still present but significantly diminished, the score will remain at 3; despite an endoscopically appreciable change in activity, the improvement is not captured by the score in isolation. Using the UCEIS to evaluate the same patient, the erosion/ulceration subscore would be 3 for the initial endoscopy but would be likely to fall to 2 at the time of repeat, objectively documenting improvement. This type of ability to detect a (potentially) meaningful change in health status epitomizes the responsiveness of a more optimal index. 13 However, despite these potential benefits, many gastroenterologists still prefer to use the MES. This is, in part, because the scores are more readily applicable to clinical decision-making. For example, an endoscopic Mayo score of 2 or above is generally accepted as the threshold for need for treatment optimization/escalation or addition of more potent agents. 2 The equivalent UCEIS threshold is not yet clearly understood, and this may currently limit its clinical utility. Therefore, the primary aim of this study was to determine a UCEIS cutoff at which treatment escalation or optimization should be considered. Our secondary aim was to contribute to the external validation of the UCEIS by evaluating its relationship with other validated measures of disease activity. This included clinical disease activity using the Simple Clinical Colitis Activity Index (SCCAI), 14 biochemical disease activity using serum C-reactive protein (CRP) levels, and histopathological disease activity using the recently defined Nancy Histological Index (NHI). 15 Finally, our study also hoped to add to the external validation of the NHI, which was derived by validation against established histological scores 15 but not against measures of endoscopic or clinical disease activity. The NHI consists of 3 histopathological criteria: ulceration, acute inflammatory cells infiltrate, and chronic inflammatory cells infiltrate, with outcomes varying from grade 0 to grade 4 (with 0-1 denoting inactive or quiescent disease and 2, 3, and 4 denoting mild, moderate, and severe activity, respectively). It is simple to use, appears responsive, and has good intra-and interobserver reliability. These factors mean that it is likely to be the most appropriate histological index for use in day-today clinical practice. Moreover, as histological healing has been demonstrated to associate with improved clinical outcomes in UC, 16, 17 it could therefore be considered a therapeutic goal.
METHODS

Patients
By interrogation of the electronic reporting software (Endosoft) used at Guy's and St Thomas' Hospital in London, a database was generated containing all endoscopies performed for UC between November 2016 (when routine use of the UCEIS was initiated) and January 2018. Specifically, both flexible sigmoidoscopies and colonoscopies were included. Endoscopies for IBD-U (inflammatory bowel disease unclassified) were also included, but patients with Crohn's disease, diverticular colitis, a rectal stump, or ileoanal pouch were excluded. In cases where UCEIS was recorded in the endoscopy report, demographic, disease phenotype, and treatment-related information was collected. If a single patient had multiple endoscopies with the UCEIS documented, both/all procedures were included.
Endoscopic Evaluation
Patients who underwent a colonoscopy were prepared for the procedure in the standard manner using either polyethylene glycol or sodium picosulphate and senna. Those undergoing a flexible sigmoidoscopy were prepared with a phosphate enema. Experienced IBD clinical research fellows or consultant gastroenterologists who were familiar with the use of the UCEIS and MES conducted all endoscopies. Scores were recorded contemporaneously. As a rule, endoscopists rated the worst affected area, but in cases where more than 1 area of the colonic mucosa was scored in the report, the higher value was used in our analyses.
Treatment Alteration
Treatment at the time of procedure and treatment alteration decisions based on endoscopic findings were collected from endoscopy reports and/or subsequent correspondence, retrieved from electronic patient records. As the majority of patients were on multiple agents, only the "most potent" was used in our analyses. This was defined as the treatment that comes later in most conventional step-up approaches to the management of UC in adult patients. 18 The incremental scale we used consisted of aminosalicylates (topical or oral), thiopurines (azathioprine, mercaptopurine, or thioguanine), and biologics/ciclosporin (infliximab, adalimumab, golimumab, vedolizumab, ciclosporin), in order of ascending "potency." Whenever steroids were commenced after an endoscopy, they were considered treatment escalation (ie, a more potent treatment). Excluded from this scale and reported as "other" were methotrexate and clinical trial agents.
Treatment escalation or optimization was considered present if the most potent treatment that was used before the procedure was given in a higher dose, was changed to another agent in the same category (eg, infliximab to vedolizumab), or was changed to a treatment further on in standard treatment algorithms (eg, mesalazine to azathioprine), or if another agent was added to the current treatment (eg, prednisone added to any other treatment). Treatment de-escalation was considered present if treatments were withdrawn after the procedures or if the treatment was given in a lower dose.
Measures of Clinical, Biochemical, and Histological Disease Activity
Clinical disease activity was evaluated using the SCCAI, with scores ranging from 0 to 19 points. 19 The SCCAI was collected, where present, from endoscopy reports, and otherwise from clinic letters and/or medical charts generated a maximum of 4 weeks before the procedure. C-reactive protein was collected if it had been measured within 4 weeks before the procedure. Nancy Histological Index score was included in cases where endoscopic biopsies were taken and had been scored by the reporting pathologist.
Statistical Analysis
The measure of agreement between the UCEIS and the Mayo score was examined using Kappa. This was achieved by stratification of the UCEIS into 4 categories to match the Cutoff points for the UCEIS and NHI regarding treatment escalation were calculated using ROC curve analysis. Using this threshold to divide patients into "escalation" and "nonescalation" groups, a 2 × 2 crosstab was derived and analyzed using the Pearson chi-square test. The accuracy of our proposed UCEIS and NHI thresholds was evaluated using area under the curve (AUC) analysis.
The Pearson correlation coefficient (r) was used to compare the linear relationship between the UCEIS and SCCAI, CRP, calprotectin, and NHI. The following established definitions for strength of correlation were used: <0.50 weak, 0.50-0.70 moderate, 0.70-0.90 strong, and >0.90 very strong. 20 Statistical Package of the Social Sciences 25.0 (SPSS) was used to perform all statistical analyses, with a predefined 2-sided significance limit of P < 0.05.
RESULTS
During the data collection period, a total of 363 endoscopies were performed in 295 patients. The procedural and demographic details and disease characteristics of the patients are summarized in Table 1 . In brief, the majority of patients underwent endoscopy for assessment of disease activity, most frequently by flexible sigmoidoscopy. The vast majority had UC (261, 88%), with a small minority (34, 12%) having IBD-U. The most potent therapy used before endoscopy was mesalazine in 34%, with biologics in 33%, steroids in 13%, and thiopurines in 10%; 9% of patients were on no regular treatment before the procedure. Where quiescent disease was found (UCEIS 0), 70% was established by colonoscopies, compared with 30% by sigmoidoscopies, most likely reflecting the cohort of patients undergoing dysplasia surveillance with dyespray colonoscopy. All other stratifications of the UCEIS 1-8 were more prevalent in sigmoidoscopies. The median UCEIS at colonoscopy (interquartile range) was 1 (0-3), compared with a median of 4 (1-5) at sigmoidoscopy.
Agreement Between UCEIS and Mayo Endoscopic Scores
Of the 363 endoscopies included, 201 (56%) documented both UCEIS and MES. The frequencies of each MES grade and the corresponding UCEIS distribution are shown in Table 2 . By subdividing the 9 stratifications of the UCEIS (0-8) to the 4 grades of the MES (0-3), agreement between the 2 scores was demonstrated to be substantial (κ = 0.713; P < 0.001).
UCEIS Threshold for Treatment Escalation
Decisions regarding the necessity for treatment escalation or optimization were available for 355 procedures (97%).
Overall, treatment escalation was considered necessary after 199 (56%) procedures. Using ROC curve analysis, a UCEIS threshold denoting the perceived need for treatment escalation or optimization was defined (Fig. 2) . The UCEIS cutoff point that demonstrated optimal sensitivity and specificity (0.80 and 0.90, respectively) was a score of ≥3.5, which, for practical purposes, was interpreted as a UCEIS ≥4. To determine the robustness of this threshold, our cohort was examined to assess whether patients with a UCEIS ≥4 were indeed more likely to require treatment escalation than those with a UCEIS <4. By dichotomizing the procedures into "UCEIS 0-3" and "UCEIS 4-8" groups, a 2 × 2 crosstab was generated and analyzed (Table 3) . Of 170 patients with a UCEIS ≥4, treatment escalation was considered necessary for 159 (94%), compared with 11 (6%) in whom it was not. Of 185 patients with a UCEIS ≤3, treatment escalation was considered necessary in 40 (22%) cases, but was not in 145 (78%; P < 0.001). The resulting AUC was 0.93. 
UCEIS Validation
Correlation Between the UCEIS and SCCAI and CRP
SCCAI and CRP were available for 94 (26%) and 162 (45%) procedures, respectively. A moderate correlation was observed between UCEIS and SCCAI values (r = 0.67; P < 0.001) (Supplementary Fig. 1 ). However, the observed correlation between CRP values and UCEIS scores was weak (r = 0.279; P < 0.001) (Supplementary Fig. 2 ). Both SCCAI and MES were available in 61 (17%) procedures, where we also found a moderate correlation between the 2 indices (r = 0.59; P < 0.001). C-reactive protein was available in 81 procedures where the MES was scored. The observed correlation was weak and did not reach statistical significance (r = 0.187; P = 0.095).
Nancy Histological Index
Biopsies were obtained in 191 procedures (53%), of which 104 (54%) were acquired in patients with a UCEIS ≥4 and 87 (46%) in patients with a UCEIS ≤3. The NHI was evaluated and recorded in the histology report for 97 of the 192 (51%) samples. Of these, 66 (68%) had a UCEIS ≥4, compared with 31 (32%) who had a UCEIS ≤3. UCEIS and NHI scores demonstrated a strong correlation (r = 0.723; P < 0.001) ( Supplementary  Fig. 3 ). Receiver operating characteristic curve analysis of these data was carried out to define an NHI cutoff for the perceived need for treatment escalation (Fig. 3) . The most optimal sensitivity and specificity (0.90 and 0.74, respectively; AUC, 0.81) were found at an NHI of ≥2.5, which, for practical purposes, was interpreted as an NHI ≥3. A 2 × 2 crosstab was made to analyze the difference between the 2 NHI groups based on this threshold: NHI 0-2 and NHI 3-4 (Table 4) . No patients with an NHI of 0 required any treatment escalation. Those with an NHI of 1 or 2 were escalated approximately half of the time (40% and 56%, respectively), whereas almost all patients with an NHI of 3 or 4 required escalation based on endoscopic appearances (95% and 90%, respectively). NHI scores, corresponding UCEIS scores, and the perceived need for treatment escalation are summarized in Supplementary Table 1 . Overall, a UCEIS ≥4 could be considered likely to predict moderate to severe histological activity (NHI 3-4).
DISCUSSION
The primary aim of this study was to define a UCEIS threshold to guide clinical decision-making based upon endoscopic appearances. Among our data set of 363 procedures, we observed that a UCEIS of 4 or above was most closely associated with the perceived need for treatment escalation or optimization based upon endoscopic findings. Understanding where this threshold lies is a potentially important operating characteristic of the UCEIS that was previously not well defined. We also aimed to add external validity to the UCEIS by assessing its agreement with another endoscopic index (MES) and its correlation with clinical, biochemical, and histological indices. Our results demonstrated substantial agreement with the MES, strong correlation with the NHI, moderate correlation with the SCCAI, and weak correlation with CRP. In addition, our results added external validity to the NHI and indicated that a score of 3 or above was associated with the need for treatment escalation.
Other groups have also endeavored to better define the operating characteristics of the UCEIS and in doing so have demonstrated potential prognostic benefits compared with the MES. 10, 11 Nevertheless, there remains a paucity of evidence to inform clinical management decisions based on UCEIS values. An exception is the study performed by Corte et al. that suggests that a UCEIS ≥7 in the setting of acute severe UC should be used as an indicator of the need to escalate to infliximab or ciclosporin. 21 However, aside from this threshold, which is only applicable in a specific clinical scenario, there are few recommendations to guide practice. In an article describing the development of the UCEIS, Travis et al. suggest that remission might be defined as a score of 0 for all 3 descriptors (allowing blurring or loss of capillary margins with a recognizable vascular pattern, no visible bleeding, and no erosions or ulceration). They also propose that "severe disease" might be defined as a level of at least 2 for vascular pattern and bleeding, with 1 for erosions and ulcers (total score ≥5). 8 However, neither of these potential thresholds was examined further at the point of initial internal validation, 9 nor have they been externally validated. This lack of full understanding of the UCEIS' operating characteristics led the IOIBD STRIDE initiative to recommend the MES rather than the UCEIS when defining the endoscopic target for "treat-to-target" strategies. It should be recognized that STRIDE also recommended that "the UCEIS should be scored alongside endoscopic Mayo values in future trials, to further investigate the additional value and operating characteristics of the index" and that this recommendation formed the basis of the study described here. 2 In addition to endoscopic healing, the relevance of histological healing in UC is becoming increasingly appreciated. Although insufficient evidence existed for STRIDE to recommend it as a treatment goal, it has been linked to favorable outcomes and lower rates of disease-related complications. 16, 22 Furthermore, histological inflammation seems to be better at predicting clinical outcomes than endoscopic inflammation. 16 In their systematic review, Bryant et al. found that 16%-100% of UC patients still had microscopic inflammation, despite their endoscopy showing quiescent disease. 17 We therefore sought to understand the relationship between endoscopic activity (as measured using the UCEIS) and histological activity. For this we used the NHI, a novel, validated, simplified histological disease activity index. 15 We observed a strong correlation between the scores, that moderate to severe histological activity (NHI 3 or 4) could be predicted by a UCEIS ≥4, and that it was associated with the perceived need for treatment escalation (based solely on endoscopic features). Of note among our observations was that all cases graded as UCEIS 0 predicted an NHI of 0 (Supplementary Table 1 ). Although this finding was applicable to only a small number of procedures (n = 3), it suggests that biopsies taken specifically to confirm complete histological remission (NHI 0) could possibly be avoided in patients with a UCEIS of 0. This group could be predicted, with reasonable confidence, to have no or only mild increases in lymphocytes, plasmocytes, and/or eosinophils. This is potentially clinically relevant as basal plasmacytosis has previously been shown to predict relapse (P = 0.007). 22 Rationalizing the use of endoscopic biopsies in this way could help reduce unnecessary costs incurred by endoscopy departments.
The SCCAI is a validated clinical disease activity index that is quick and easy to administer. 19 It has previously been shown to predict endoscopic disease activity in UC, as judged by the MES, with moderate correlation (r = 0.55) between the 2. 23 However, to the best of our knowledge, ours is the first study to examine its relationship with the UCEIS. We observed that the SCCAI correlated moderately (r = 0.67) with UCEIS values, which appeared similar to its correlation with MES (r = 0.59). The relative lack of strength of this observed correlation suggests that while symptom assessments are certainly helpful in the management of UC, objective markers of inflammation such as endoscopy (or calprotectin) also have a role to play in achieving/confirming disease control.
C-reactive protein is a minimally invasive and inexpensive way of monitoring disease activity in IBD. Although elevated levels of CRP are more often found in the transmural inflammation that characterizes Crohn's disease, they are often also present in severe, extensive UC. However, previous studies have demonstrated only moderate correlation with endoscopic activity (MES) in the context of mild or moderate UC. 24, 25 This is broadly in keeping with our own finding of a weak correlation between UCEIS and CRP, which therefore appears to have limited value as a biomarker of disease activity in UC. 26 Although our study is novel, has several strengths, and addresses a clinically relevant issue, it also has several limitations. Despite endoscopic and clinical scores being prospectively recorded on endoscopic reporting software and electronic patient records, these data were only collected retrospectively, resulting in a significant amount of missing data. This included missing SCCAI and CRP values and NHI scores, with biopsies only being taken in around half of all procedures and the NHI only being recorded in approximately half of all histology reports. In addition, although correlation with fecal calprotectin would have been of great interest and would have added further validity to the UCEIS, there were too few data in this regard to draw any meaningful conclusions (measured in only 34 cases, 9%), and this was therefore not included in our analyses. Another limitation is that we included endoscopic assessments made by a relatively large number of endoscopists, and although the interobserver reliability of the UCEIS is thought to be satisfactory, 9 we do not necessarily know this to be the case among these operators, particularly as some procedures were carried out by less experienced endoscopists (IBD clinical research fellows). Our included group of procedures was also heterogenous, consisting of a mixture of flexible sigmoidoscopies and colonoscopies carried out for different indications (eg, activity assessment and/or dysplasia surveillance). It is also possible that the use of steroids before procedures may have biased our results by temporarily improving symptoms and endoscopic inflammation, thereby reducing the likelihood of treatment escalation. However, the impact of this would have been marginal in view of the relatively small minority of patients on steroids (13%). Finally, in addition to UC, we also included a small number of scopes carried out in patients with IBD-U, for whom no endoscopic index has been formally validated. Nonetheless, these patients still require objective endoscopic assessment, and by virtue of the fact that the pattern and distribution of their inflammation often closely resembles UC, we felt it pragmatic and acceptable to include them. Of note, all treatment escalation decisions among IBD-U patients were driven by findings in the colon (rather than active ileitis) and would therefore have been captured in their UCEIS.
Based on our findings, we propose a UCEIS score of 4 or above as the endoscopic threshold to consider treatment escalation. Interestingly, the group in Oxford who devised the UCEIS has also arbitrarily used the same threshold recently to define active disease in a study investigating the utility of fecal calprotectin. 27 However, that is not to say that a symptomatic patient with a UCEIS of 3 or below should not be escalated. We have also avoided inferring that a UCEIS of 3 or below should necessarily be considered endoscopic remission. Indeed, a patient with a UCEIS of 3 could conceivably still have deep ulceration (although this finding in the absence of bleeding or loss of vascular pattern is uncommon). Perhaps a more appropriate definition would be a UCEIS of 3 or below with no individual subscore >1. However, this and our proposed threshold of ≥4 for treatment escalation should be interpreted within the context of the limitations of our study and clearly require validation in other (larger) data sets and prospective studies.
CONCLUSIONS
The UCEIS is a novel, valid, and reproducible endoscopic index that demonstrates substantial agreement with the more established Mayo endoscopic score and correlates strongly with histological activity (measured using the NHI). Where endoscopic evaluation is considered necessary, the objective information it provides should be taken into account when making treatment adjustment decisions. Based on our findings, a threshold of 4 or more may be used to prompt consideration of treatment escalation or optimization.
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